Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2
This article was originally published in The Tan Sheet
Executive Summary
Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year
You may also be interested in...
Triaminic Allerchews
Upcoming late January launch of 10 mg loratadine quick-dissolve, wintergreen-flavored tablets under Triaminic children's cough/cold line may provide Novartis Consumer Healthcare's OTC unit with a strong start to 2004 sales. Triaminic Allerchews will debut in 8- and 24-count packages with substantial consumer and trade promotion support, Novartis says. The product will compete against Schering-Plough's Claritin Children's Formula Syrup, which contains 5 mg loratadine per dose (1"The Tan Sheet" July 28, 2003, p. 11)...
Novartis Triaminic Allerchews With Loratadine Slated To Launch In 2004
Novartis' Triaminic children's cough/coldline will be extended in early 2004 with Allerchews, the brand's first loratadine-containing offering. The product debuted at the National Association of Chain Drug Stores Marketplace in San Diego June 8-10
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC